POU6F2 is a transcription factor that recognizes the DNA sequence 5'-ATGCAAAT-3' and plays critical roles in retinal development and multiple cancer pathways. During kidney embryogenesis, POU6F2 expression is temporally and spatially regulated, with highest expression in early developmental stages (E13), paralleling renal organogenesis and colocalizing with WT1 protein 1. In the retina, POU6F2 labels specific ganglion cell populations, including novel ON-OFF directionally selective ganglion cells and parasol ganglion cells forming the magnocellular pathway 2. Disease relevance is substantial across multiple cancer types. POU6F2 is overexpressed in approximately 23% of Wilms tumors 1, consistent with its hereditary susceptibility association. In gastric adenocarcinoma, POU6F2 promotes liver metastasis through dual mechanisms: transcriptional upregulation of SNAI1 (EMT inducer) and IGF2-mediated conversion of hepatic stellate cells to cancer-associated fibroblasts 3. Additionally, somatic POU6F2 mutations have been identified in aggressive prolactinomas, where loss of POU6F2 function increases cell proliferation and prolactin secretion 4. Clinically, POU6F2 dysfunction associates with glaucoma, myopia, and dyslexia risk 2. Notably, POU6F2-positive retinal ganglion cells show preferential vulnerability to elevated intraocular pressure-induced damage 2. Upstream regulatory mechanisms include METTL3-mediated m6A modification in colorectal cancer 5, while downstream regulatory networks involve miRNA interactions affecting cancer progression across multiple tumor types.